Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma

BackgroundThe tumor immune microenvironment has clinicopathological significance in predicting prognosis and therapeutic efficacy. We aimed to develop an immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma (NPC).MethodsUsing multiplexed quantitative fluorescence,...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2020-04, Vol.8 (1), p.e000205
Main Authors: Liu, Sai-Lan, Bian, Li-Juan, Liu, Ze-Xian, Chen, Qiu-Yan, Sun, Xue-Song, Sun, Rui, Luo, Dong-Hua, Li, Xiao-Yun, Xiao, Bei-Bei, Yan, Jin-Jie, Lu, Zi-Jian, Yan, Shu-Mei, Yuan, Li, Tang, Lin-Quan, Li, Jian-Ming, Mai, Hai-Qiang
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Automation
Cancer
Cancer therapies
Immunotherapy
Immunotherapy Biomarkers
Lymphocytes
Medical prognosis
Metastasis
Neutrophils
Nomograms
Radiation therapy
Throat cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe tumor immune microenvironment has clinicopathological significance in predicting prognosis and therapeutic efficacy. We aimed to develop an immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma (NPC).MethodsUsing multiplexed quantitative fluorescence, we detected 17 immune biomarkers in a primary screening cohort of 54 NPC tissues presenting with/without distant metastasis following radical therapy. The LASSO (least absolute shrinkage and selection operator) logistic regression model used statistically significant survival markers in the training cohort (n=194) to build an immune signature. The prognostic and predictive accuracy of it was validated in an external independent group of 304 patients.ResultsEight statistically significant markers were identified in the screening cohort. The immune signature consisting of four immune markers (PD-L1+ CD163+, CXCR5, CD117) in intratumor was adopted to classify patients into high and low risk in the training cohort and it showed a high level of reproducibility between different batches of samples (r=0.988 for intratumor; p
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2019-000205